S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Stocks are for suckers – try this instead (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
Stocks are for suckers – try this instead (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Biden, GOP reach debt-ceiling deal, now Congress must approve it to prevent calamitous default
BREAKING: Tiny biotech successfully treats blindness (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Stocks are for suckers – try this instead (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
Stocks are for suckers – try this instead (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Biden, GOP reach debt-ceiling deal, now Congress must approve it to prevent calamitous default
BREAKING: Tiny biotech successfully treats blindness (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Stocks are for suckers – try this instead (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
Stocks are for suckers – try this instead (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Biden, GOP reach debt-ceiling deal, now Congress must approve it to prevent calamitous default
BREAKING: Tiny biotech successfully treats blindness (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Stocks are for suckers – try this instead (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
Stocks are for suckers – try this instead (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Biden, GOP reach debt-ceiling deal, now Congress must approve it to prevent calamitous default
BREAKING: Tiny biotech successfully treats blindness (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
OTCMKTS:PMCB

PharmaCyte Biotech (PMCB) Stock Forecast, Price & News

$3.15
+0.04 (+1.29%)
(As of 05/26/2023 ET)
Compare
Today's Range
$3.10
$3.15
50-Day Range
$2.74
$3.15
52-Week Range
$1.95
$3.15
Volume
73,523 shs
Average Volume
79,519 shs
Market Capitalization
$54.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

PMCB stock logo

About PharmaCyte Biotech (OTCMKTS:PMCB) Stock

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.

Receive PMCB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter.

PMCB Stock News Headlines

PharmaCyte Biotech (OTCMKTS:PMCB) Shares Up 0.4%
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Biotech ETFs’ Performance Deserves A Look
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
PharmaCyte to evaluate opportunities; CEO steps down
PharmaCyte Biotech Shares Reverse Course, Drop 8%
See More Headlines
Receive PMCB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter.

PMCB Company Calendar

Last Earnings
12/15/2021
Today
5/28/2023
Fiscal Year End
4/30/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PMCB
Employees
4
Year Founded
1996

Profitability

Net Income
$-4,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.34 per share

Miscellaneous

Free Float
16,461,000
Market Cap
$54.94 million
Optionable
Not Optionable
Beta
-0.03

Social Links


Key Executives

  • Joshua Nathaniel Silverman
    Chairman, President & Chief Executive Officer
  • Carlos A. Trujillo
    Chief Financial Officer
  • José L. Iglesias
    Chief Medical Officer
  • Lilli Brandtner
    Director-Diabetes Program Development













PMCB Stock - Frequently Asked Questions

How have PMCB shares performed in 2023?

PharmaCyte Biotech's stock was trading at $2.93 at the beginning of the year. Since then, PMCB stock has increased by 7.5% and is now trading at $3.15.
View the best growth stocks for 2023 here
.

How were PharmaCyte Biotech's earnings last quarter?

PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) released its quarterly earnings data on Wednesday, December, 15th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01.

What other stocks do shareholders of PharmaCyte Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PharmaCyte Biotech investors own include Co-Diagnostics (CODX), iBio (IBIO), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Vaxart (VXRT), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), OWC Pharmaceutical Research (OWCP), VBI Vaccines (VBIV) and Novavax (NVAX).

What is PharmaCyte Biotech's stock symbol?

PharmaCyte Biotech trades on the OTCMKTS under the ticker symbol "PMCB."

Who are PharmaCyte Biotech's major shareholders?

PharmaCyte Biotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include K2 Principal Fund L.P. (4.15%), Simplex Trading LLC (0.00%), BlackRock Inc. (0.25%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%) and Dimensional Fund Advisors LP (0.17%).

How do I buy shares of PharmaCyte Biotech?

Shares of PMCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PharmaCyte Biotech's stock price today?

One share of PMCB stock can currently be purchased for approximately $3.15.

How much money does PharmaCyte Biotech make?

PharmaCyte Biotech (OTCMKTS:PMCB) has a market capitalization of $54.94 million. The company earns $-4,240,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

How can I contact PharmaCyte Biotech?

PharmaCyte Biotech's mailing address is 23046 AVENIDA DE LA CARLOTA SUITE 600, LAGUNA HILLS CA, 92653. The official website for the company is www.pharmacyte.com. The company can be reached via phone at (917) 595-2850, via email at info@pharmacyte.com, or via fax at 917-595-2851.

This page (OTCMKTS:PMCB) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -